CD163 and neoplasm: In the majority of cancers, the macrophage marker CD163 correlates with more advanced tumours and to a worse prognostic outcome, except in the cases of gastric cancer and colorectal cancers.1–4 Other markers, such as CD68, have been used to stain macrophages, but have been linked to both favourable and unfavourable outcomes.4,5